Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2019, Article ID 5836476, 14 pages
https://doi.org/10.1155/2019/5836476
Research Article

Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis

1Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, WAO Center of Excellence, Naples, Italy
2Endocannabinoid Research Group, Istituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche (ICB-CNR), Pozzuoli, Italy
3Division of Allergy and Clinical Immunology, University of Salerno, Italy
4Department of Public Health, University of Naples Federico II, Italy
5Monaldi Hospital Pharmacy, Naples, Italy
6Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Centre de Recherche de l’Institut Universitaire de Cardiologie et Pneumologie de Quèbec, and Institut sur la Nutrition et les Aliments Fonctionnels, Québec City, Canada

Correspondence should be addressed to Maria Rosaria Galdiero; ti.aninu@oreidlag.airasorairam

Received 30 October 2018; Revised 2 April 2019; Accepted 14 May 2019; Published 1 July 2019

Academic Editor: Enrique Ortega

Copyright © 2019 Anne Lise Ferrara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Valent, C. Akin, L. Escribano et al., “Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria,” European Journal of Clinical Investigation, vol. 37, no. 6, pp. 435–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. D. D. Metcalfe and Y. A. Mekori, “Pathogenesis and pathology of mastocytosis,” Annual Review of Pathology, vol. 12, no. 1, pp. 487–514, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Valent, C. Akin, K. Hartmann et al., “Advances in the classification and treatment of mastocytosis: current status and outlook toward the future,” Cancer Research, vol. 77, no. 6, pp. 1261–1270, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Valent, C. Akin, and D. D. Metcalfe, “Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts,” Blood, vol. 129, no. 11, pp. 1420–1427, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Akin, “Mast cell activation syndromes,” The Journal of Allergy and Clinical Immunology, vol. 140, no. 2, pp. 349–355, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Schuch and K. Brockow, “Mastocytosis and anaphylaxis,” Immunology and Allergy Clinics of North America, vol. 37, no. 1, pp. 153–164, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. D. D. Metcalfe, “Mast cells and mastocytosis,” Blood, vol. 112, no. 4, pp. 946–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. C. Moon, A. D. Befus, and M. Kulka, “Mast cell mediators: their differential release and the secretory pathways involved,” Frontiers in Immunology, vol. 5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Murakami and Y. Taketomi, “Secreted phospholipase A2 and mast cells,” Allergology International, vol. 64, no. 1, pp. 4–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Zhu, J. Zou, T. Li et al., “Differential Roles of Phospholipase D Proteins in FcεRI-Mediated Signaling and Mast Cell Function,” Journal of Immunology, vol. 195, no. 9, pp. 4492–4502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Ramrakhiani and S. Chand, “Recent progress on phospholipases: different sources, assay methods, industrial potential and pathogenicity,” Applied Biochemistry and Biotechnology, vol. 164, no. 7, pp. 991–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: From cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. B. Fisher and M. Jain, Phospholipases: Degradation of Phospholipids in Membranes and Emulsions, eLS, 2009.
  14. T. O. Eichmann and A. Lass, “DAG tales: the multiple faces of diacylglycerol--stereochemistry, metabolism, and signaling,” Cellular and Molecular Life Sciences, vol. 72, no. 20, pp. 3931–3952, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Boyce, “Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation,” Immunological Reviews, vol. 217, no. 1, pp. 168–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Aloe, A. Leon, and R. Levi-Montalcini, “A proposed autacoid mechanism controlling mastocyte behaviour,” Agents and Actions, vol. 39, no. S1, pp. C145–C147, 1993. View at Publisher · View at Google Scholar · View at Scopus
  17. S. P. Chock, E. A. Schmauder-Chock, E. Cordella-Miele, L. Miele, and A. B. Mukherjee, “The localization of phospholipase A2 in the secretory granule,” The Biochemical Journal, vol. 300, no. 3, pp. 619–622, 1994, Pt 3. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Triggiani, G. Giannattasio, C. Calabrese et al., “Lung mast cells are a source of secreted phospholipases A2,” Journal of Allergy and Clinical Immunology, vol. 124, no. 3, pp. 558–565.e3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Granata, V. Nardicchi, S. Loffredo et al., “Secreted phospholipases A(2): a proinflammatory connection between macrophages and mast cells in the human lung,” Immunobiology, vol. 214, no. 9-10, pp. 811–821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. T. S. Hallstrand, Y. Lai, Z. Ni et al., “Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity,” Clinical and Experimental Allergy, vol. 41, no. 6, pp. 801–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Granata, R. I. Staiano, S. Loffredo et al., “The role of mast cell-derived secreted phospholipases A2 in respiratory allergy,” Biochimie, vol. 92, no. 6, pp. 588–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Dennis, J. Cao, Y. H. Hsu, V. Magrioti, and G. Kokotos, “Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention,” Chemical Reviews, vol. 111, no. 10, pp. 6130–6185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Menschikowski, A. Hagelgans, U. Schuler, S. Froeschke, A. Rosner, and G. Siegert, “Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers,” Pathology Oncology Research, vol. 19, no. 4, pp. 839–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Murakami, K. Yamamoto, Y. Miki, R. Murase, H. Sato, and Y. Taketomi, “The roles of the secreted phospholipase A2 gene family in immunology,” Advances in Immunology, vol. 132, pp. 91–134, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Brglez, G. Lambeau, and T. Petan, “Secreted phospholipases A2 in cancer: diverse mechanisms of action,” Biochimie, vol. 107, Part A, pp. 114–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Bernard and D. Vindrieux, “PLA2R1: expression and function in cancer,” Biochimica et Biophysica Acta, vol. 1846, no. 1, pp. 40–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Boilard, S. G. Bourgoin, C. Bernatchez, P. E. Poubelle, and M. E. Surette, “Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans,” The FASEB Journal, vol. 17, no. 9, pp. 1068–1080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Fujita, K. Zhu, C. K. Fujita et al., “Proinflammatory Secreted Phospholipase A2 Type IIA (sPLA-IIA) Induces Integrin Activation through Direct Binding to a Newly Identified Binding Site (Site 2) in Integrins αvβ3, α4β1, and α5β1,” Journal of Biological Chemistry, vol. 290, no. 1, pp. 259–271, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Lambeau and M. H. Gelb, “Biochemistry and physiology of mammalian secreted phospholipases A2,” Annual Review of Biochemistry, vol. 77, no. 1, pp. 495–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Murakami, N. Hara, I. Kudo, and K. Inoue, “Triggering of degranulation in mast cells by exogenous type II phospholipase A2,” The Journal of Immunology, vol. 151, no. 10, pp. 5675–5684, 1993. View at Google Scholar
  31. J. D. Morrow, C. Guzzo, G. Lazarus, J. A. Oates, and L. Jackson Roberts II, “Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2,” Journal of Investigative Dermatology, vol. 104, no. 6, pp. 937–940, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. R. J. T. OUWENDIJK, F. J. ZIJLSTRA, J. H. P. WILSON, I. L. BONTA, J. E. VINCENT, and E. STOLZ, “Raised plasma levels of thromboxane B2in systemic mastocytosis,” European Journal of Clinical Investigation, vol. 13, no. 3, pp. 227–229, 1983. View at Publisher · View at Google Scholar · View at Scopus
  33. J. D. Morrow, J. A. Oates, L. Jackson Roberts II et al., “Increased Formation of ThromboxaneIn Vivo in Humans with Mastocytosis,” The Journal of Investigative Dermatology, vol. 113, no. 1, pp. 93–97, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Akin and D. D. Metcalfe, “Surrogate markers of disease in mastocytosis,” International Archives of Allergy and Immunology, vol. 127, no. 2, pp. 133–136, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Xiao, J.-i. Kashiwakura, H. Hong et al., “Phospholipase C-β3 Regulates FcɛRI-Mediated Mast Cell Activation by Recruiting the Protein Phosphatase SHP-1,” Immunity, vol. 34, no. 6, pp. 893–904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Peng and M. A. Beaven, “An essential role for phospholipase D in the activation of protein kinase C and degranulation in mast cells,” Journal of Immunology, vol. 174, no. 9, pp. 5201–5208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Chahdi, W. S. Choi, Y. M. Kim, P. F. Fraundorfer, and M. A. Beaven, “Serine/threonine protein kinases synergistically regulate phospholipase D1 and 2 and secretion in RBL-2H3 mast cells,” Molecular Immunology, vol. 38, no. 16-18, pp. 1269–1276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Lin, W. J. Fung, and A. M. Gilfillan, “Phosphatidylcholine-specific phospholipase D-derived 1,2-diacylglycerol does not initiate protein kinase C activation in the RBL 2H3 mast-cell line,” The Biochemical Journal, vol. 287, no. 1, pp. 325–331, 1992, Pt 1. View at Publisher · View at Google Scholar · View at Scopus
  39. D. A. Kennerly, “Phosphatidylcholine is a quantitatively more important source of increased 1,2-diacylglycerol than is phosphatidylinositol in mast cells,” The Journal of Immunology, vol. 144, no. 10, pp. 3912–3919, 1990. View at Google Scholar
  40. M. Reisenberg, P. K. Singh, G. Williams, and P. Doherty, “The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 367, no. 1607, pp. 3264–3275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. R. I. Staiano, S. Loffredo, F. Borriello et al., “Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors,” Journal of Leukocyte Biology, vol. 99, no. 4, pp. 531–540, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Luchicchi and M. Pistis, “Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids,” Molecular Neurobiology, vol. 46, no. 2, pp. 374–392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Facci, R. Dal Toso, S. Romanello, A. Buriani, S. D. Skaper, and A. Leon, “Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3376–3380, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. W. R. Sperr, J. H. Jordan, M. Fiegl et al., “Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease,” International Archives of Allergy and Immunology, vol. 128, no. 2, pp. 136–141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. S. D. Skaper, L. Facci, and P. Giusti, “Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator,” Molecular Neurobiology, vol. 48, no. 2, pp. 340–352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. D. De Filippis, A. D’Amico, M. P. Cinelli, G. Esposito, V. Di Marzo, and T. Iuvone, “Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats,” Journal of Cellular and Molecular Medicine, vol. 13, no. 6, pp. 1086–1095, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Roviezzo, A. Rossi, E. Caiazzo et al., “Palmitoylethanolamide supplementation during sensitization prevents airway allergic symptoms in the mouse,” Frontiers in Pharmacology, vol. 8, p. 857, 2017. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Cerrato, P. Brazis, M. F. della Valle, A. Miolo, and A. Puigdemont, “Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells,” Veterinary Immunology and Immunopathology, vol. 133, no. 1, pp. 9–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. A. H. Y. Lau and S. S. M. Chow, “Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells,” European Journal of Pharmacology, vol. 464, no. 2-3, pp. 229–235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. G. A. Cabral, G. A. Ferreira, and M. J. Jamerson, “Endocannabinoids and the immune system in health and disease,” Handbook of Experimental Pharmacology, vol. 231, pp. 185–211, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. S. L. Cruz, E. Sanchez-Miranda, J. I. Castillo-Arellano, R. D. Cervantes-Villagrana, A. Ibarra-Sanchez, and C. Gonzalez-Espinosa, “Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB2 and GPR55 receptor activation. Possible involvement of CB2-GPR55 heteromers,” International Immunopharmacology, vol. 64, pp. 298–307, 2018. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Pardanani, “Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management,” American Journal of Hematology, vol. 91, no. 11, pp. 1146–1159, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Arock, K. Sotlar, C. Akin et al., “KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis,” Leukemia, vol. 29, no. 6, pp. 1223–1232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Matias, G. Carta, E. Murru, S. Petrosino, S. Banni, and V. Di Marzo, “Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes,” Biochimica et Biophysica Acta, vol. 1781, no. 1-2, pp. 52–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Piscitelli, G. Carta, T. Bisogno et al., “Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice,” Nutrition & Metabolism (London), vol. 8, no. 1, p. 51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. K. H. Lim, A. Tefferi, T. L. Lasho et al., “Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors,” Blood, vol. 113, no. 23, pp. 5727–5736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. J. H. Butterfield, “Survey of aspirin administration in systemic mastocytosis,” Prostaglandins & Other Lipid Mediators, vol. 88, no. 3-4, pp. 122–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Pardanani, “How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage),” Blood, vol. 121, no. 16, pp. 3085–3094, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Kikawada, J. V. Bonventre, and J. P. Arm, “Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2alpha activation,” Blood, vol. 110, no. 2, pp. 561–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Murakami, I. Kudo, and K. Inoue, “Eicosanoid generation from antigen-primed mast cells by extracellular mammalian 14-kDa group II phospholipase A2,” FEBS Letters, vol. 294, no. 3, pp. 247–251, 1991. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Sato, Y. Taketomi, Y. Isogai et al., “Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation,” The Biochemical Journal, vol. 421, no. 1, pp. 17–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Taketomi, N. Ueno, T. Kojima et al., “Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis,” Nature Immunology, vol. 14, no. 6, pp. 554–563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. O. Gronroos, J. H. Salonen, M. Viander, T. J. Nevalainen, and V. J. O. Laine, “Roles of group IIA phospholipase A2 and complement in killing of bacteria by acute phase serum,” Scandinavian Journal of Immunology, vol. 62, no. 4, pp. 413–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Kupert, M. Anderson, Y. Liu et al., “Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules,” BMC Cancer, vol. 11, no. 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Mallat, G. Lambeau, and A. Tedgui, “Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease,” Circulation, vol. 122, no. 21, pp. 2183–2200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. T. J. Nevalainen, L. I. Eerola, E. Rintala, V. J. O. Laine, G. Lambeau, and M. H. Gelb, “Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum,” Biochimica et Biophysica Acta, vol. 1733, no. 2-3, pp. 210–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Loffredo, A. L. Ferrara, M. Bova et al., “Secreted phospholipases A2 in hereditary angioedema with C1-inhibitor deficiency,” Frontiers in Immunology, vol. 9, p. 1721, 2018. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Matito, J. M. Morgado, I. Álvarez-Twose et al., “Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome,” PLoS One, vol. 8, no. 10, article e76116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Hallgren and G. Pejler, “Biology of mast cell tryptase. An inflammatory mediator,” The FEBS Journal, vol. 273, no. 9, pp. 1871–1895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Pacher, S. Batkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. L. SCHWARTZ, “Tryptase, a mediator of human mast cells,” The Journal of Allergy and Clinical Immunology, vol. 86, no. 4, pp. 594–598, 1990, Pt 2. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Vitte, “Human mast cell tryptase in biology and medicine,” Molecular Immunology, vol. 63, no. 1, pp. 18–24, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. H. P. McNeil, R. Adachi, and R. L. Stevens, “Mast Cell-restricted Tryptases: Structure and Function in Inflammation and Pathogen Defense,” Journal of Biological Chemistry, vol. 282, no. 29, pp. 20785–20789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. M. C. Castells, A. M. Irani, and L. B. Schwartz, “Evaluation of human peripheral blood leukocytes for mast cell tryptase,” The Journal of Immunology, vol. 138, no. 7, pp. 2184–2189, 1987. View at Google Scholar
  75. S. Jogie-Brahim, H. K. Min, Y. Fukuoka, H. Z. Xia, and L. B. Schwartz, “Expression of alpha-tryptase and beta-tryptase by human basophils,” The Journal of Allergy and Clinical Immunology, vol. 113, no. 6, pp. 1086–1092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Valent, “Mast cell activation syndromes: definition and classification,” Allergy, vol. 68, no. 4, pp. 417–424, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. L. B. Schwartz, “Diagnostic value of tryptase in anaphylaxis and mastocytosis,” Immunology and Allergy Clinics of North America, vol. 26, no. 3, pp. 451–463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Valent, H. P. Horny, M. Triggiani, and M. Arock, “Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria,” International Archives of Allergy and Immunology, vol. 156, no. 2, pp. 119–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Degousee, F. Ghomashchi, E. Stefanski et al., “Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis,” The Journal of Biological Chemistry, vol. 277, no. 7, pp. 5061–5073, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Kawakami and W. Xiao, “Phospholipase C-β in immune cells,” Advances in Biological Regulation, vol. 53, no. 3, pp. 249–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. T. S. Hallstrand, Y. Lai, K. A. Hooper et al., “Endogenous secreted phospholipase A2 group X regulates cysteinyl leukotrienes synthesis by human eosinophils,” The Journal of Allergy and Clinical Immunology, vol. 137, no. 1, pp. 268–277.e8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Granata, A. Frattini, S. Loffredo et al., “Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2,” Journal of Immunology, vol. 184, no. 9, pp. 5232–5241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Triggiani, F. Granata, A. Frattini, and G. Marone, “Activation of human inflammatory cells by secreted phospholipases A2,” Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1289–1300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Chouinard, J. S. Lefebvre, P. Navarro et al., “The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of Its hydrolysis and de novo leukotriene B4 biosynthesis,” Journal of Immunology, vol. 186, no. 5, pp. 3188–3196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Liang, Y. L. Wu, B. J. Chen, W. Zhang, Y. Tanaka, and H. Sugiyama, “The C-kit receptor-mediated signal transduction and tumor-related diseases,” International Journal of Biological Sciences, vol. 9, no. 5, pp. 435–443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Vosseller, G. Stella, N. S. Yee, and P. Besmer, “c-kit receptor signaling through its phosphatidylinositide-3'-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling,” Molecular Biology of the Cell, vol. 8, no. 5, pp. 909–922, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Kozawa, P. Blume-Jensen, C. H. Heldin, and L. Ronnstrand, “Involvement of phosphatidylinositol 3-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release,” European Journal of Biochemistry, vol. 248, no. 1, pp. 149–155, 1997. View at Publisher · View at Google Scholar · View at Scopus